ZENITH study shows sotatercept is effective for PAH patients at high risk of mortality

The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or hospitalizations for pulmonary arterial hypertension (PA) in PAH patients in functional class III or IV at high risk of mortality. Because of its "overwhelming efficacy," the trial was stopped early so all patients in the trial, including those in the placebo arm, can benefit from sotatercept. Patients in the trial will be able to receive sotatercept through the ongoing SOTERIA extension study.

Study results have not yet been published.

Read the press release here.